首页> 美国卫生研究院文献>other >REG4 Is Highly Expressed in Mucinous Ovarian Cancer: A Potential Novel Serum Biomarker
【2h】

REG4 Is Highly Expressed in Mucinous Ovarian Cancer: A Potential Novel Serum Biomarker

机译:REG4在粘液性卵巢癌中高表达:一种潜在的新型血清生物标志物。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Preoperative diagnostics of ovarian neoplasms rely on ultrasound imaging and the serum biomarkers CA125 and HE4. However, these markers may be elevated in non-neoplastic conditions and may fail to identify most non-serous epithelial cancer subtypes. The objective of this study was to identify histotype-specific serum biomarkers for mucinous ovarian cancer. The candidate genes with mucinous histotype specific expression profile were identified from publicly available gene-expression databases and further in silico data mining was performed utilizing the MediSapiens database. Candidate biomarker validation was done using qRT-PCR, western blotting and immunohistochemical staining of tumor tissue microarrays. The expression level of the candidate gene in serum was compared to the serum CA125 and HE4 levels in a patient cohort of prospectively collected advanced ovarian cancer. Database searches identified REG4 as a potential biomarker with specificity for the mucinous ovarian cancer subtype. The specific expression within epithelial ovarian tumors was further confirmed by mRNA analysis. Immunohistochemical staining of ovarian tumor tissue arrays showed distinctive cytoplasmic expression pattern only in mucinous carcinomas and suggested differential expression between benign and malignant mucinous neoplasms. Finally, an ELISA based serum biomarker assay demonstrated increased expression only in patients with mucinous ovarian cancer. This study identifies REG4 as a potential serum biomarker for histotype-specific detection of mucinous ovarian cancer and suggests serum REG4 measurement as a non-invasive diagnostic tool for postoperative follow-up of patients with mucinous ovarian cancer.
机译:卵巢肿瘤的术前诊断依赖于超声成像以及血清生物标志物CA125和HE4。但是,这些标志物在非肿瘤性疾病中可能升高,并且可能无法鉴定出大多数非浆液性上皮癌亚型。这项研究的目的是确定粘液性卵巢癌的组织型特异性血清生物标志物。从公众可获得的基因表达数据库中鉴定出具有粘液组织型特异性表达谱的候选基因,并利用MediSapiens数据库进行进一步的计算机数据挖掘。候选生物标志物的验证是通过使用qRT-PCR,蛋白质印迹和肿瘤组织微阵列的免疫组织化学染色来完成的。将候选基因在血清中的表达水平与预期收集的晚期卵巢癌患者队列中的血清CA125和HE4水平进行比较。数据库搜索将REG4鉴定为对粘液性卵巢癌亚型具有特异性的潜在生物标志物。通过mRNA分析进一步证实了上皮性卵巢肿瘤内的特异性表达。卵巢肿瘤组织阵列的免疫组织化学染色仅在粘液性癌中显示出独特的细胞质表达模式,并暗示了良性和恶性粘液性肿瘤之间的差异表达。最后,基于ELISA的血清生物标志物测定仅在粘液性卵巢癌患者中证明表达增加。这项研究将REG4鉴定为粘液性卵巢癌组织型特异性检测的潜在血清生物标志物,并建议将血清REG4测定为粘液性卵巢癌患者术后随访的一种非侵入性诊断工具。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号